Niacin (Vitamin B3) and Pancreatic Cancer: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Niacin (Vitamin B3) and Pancreatic Cancer: Latest Research 2026

This page summarizes the current state of scientific research on Niacin (Vitamin B3) in the context of Pancreatic Cancer as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your oncologist for personalized guidance.

Compound Overview

Niacin (Vitamin B3) (B Vitamin / NAD+ Precursor) — OTC supplement; prescription doses (Niaspan) FDA-approved for dyslipidemia

Mechanism of action: NAD+ precursor via Preiss-Handler pathway; GPR109A receptor agonist (flush); HDL-raising; anti-inflammatory

Current evidence level: Strong lipid data (older studies); AIM-HIGH and HPS2-THRIVE negative for CV outcomes; NAD+ boosting confirmed

2026 Research Landscape

Direct research on Niacin (Vitamin B3) specifically for Pancreatic Cancer remains limited as of 2026, though the mechanistic connections continue to be explored in laboratory settings.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Niacin (Vitamin B3) affects the biological pathways involved in Pancreatic Cancer progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Screening studies: Preclinical models are still being used to establish whether clinical investigation is warranted

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Niacin (Vitamin B3)[tiab]) AND (Pancreatic Cancer[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Niacin (Vitamin B3) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Niacin (Vitamin B3) + Pancreatic Cancer research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Pancreatic Cancer patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Niacin (Vitamin B3) for Pancreatic Cancer?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Niacin (Vitamin B3) Pancreatic Cancer' filtered to the last 2 years. The current evidence level is: Strong lipid data (older studies); AIM-HIGH and HPS2-THRIVE negative for CV outcomes; NAD+ boosting confirmed.

Are there any 2025-2026 clinical trials for Niacin (Vitamin B3) in Pancreatic Cancer?

Check ClinicalTrials.gov with 'Niacin (Vitamin B3)' as intervention and 'Pancreatic Cancer' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your oncologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Niacin (Vitamin B3) in Pancreatic Cancer changed recently?

The field evolves rapidly. The current evidence classification is: Strong lipid data (older studies); AIM-HIGH and HPS2-THRIVE negative for CV outcomes; NAD+ boosting confirmed. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.